Literatur
- 1
Julierat P, Mottet C, Pittel V et al.
Extraintestinal manifestation of Crohn's disease.
Digestion.
2007;
76
141-148
- 2
Kethu S R.
Extraintestinal manifestations of inflammatory bowel diseases.
J Clin Gastroenterol.
2006;
40
467-475
- 3
Schoepfer A M, Trummler M, Seeholzer P et al.
Discriminating IBD from IBS: comparison of the test performance of fecal markers,
blood leukocytes, CRP, and IBD antibodies.
Inflamm Bowel Dis.
2008;
14
32-39
- 4
Ardizzone S, Puttini P S, Cassinotti A et al.
Extraintestinal manifestations of inflammatory bowel disease.
Dig Liver Dis.
2008;
40 (Suppl. 2)
S253-S259
- 5
Bennett M L, Jackson J M, Jorizzo J L et al.
Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis
on time to remission. Case review of 86 patients from 2 institutions.
Medicine.
2000;
79
37-46
- 6
Claessen M M, Vleggaar F P, Tytgat K M et al.
High lifetime risk of cancer in primary sclerosing cholangitis.
J Hepatol.
2009;
50
158-164
- 7
Fickert P, Moustafa T, Trauner M.
Primary sclerosing cholangitis – the arteriosclerosis of the bile duct?.
Lipids Health Dis.
2007;
6
3
- 8
Thackeray E W, Charatcharoenwitthaya P, Elfaki D et al.
Colon neoplasms develop early in the course of inflammatory bowel disease and primary
sclerosing cholangitis.
Clin Gastroenterol Hepatol.
2011;
9
2-56
- 9
Hoffmann J C, Preiss J C, Autschbach F et al.
S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“.
Z Gastroenterol.
2008;
46
1094-1146
- 10
Miller J, Yentzer B A, Clark A et al.
Pyoderma gangrenosum: a review and update on new therapies.
J Am Acad Dermatol.
2010;
62
646-654
Ao. Univ.-Prof. Dr. med. Christoph Högenauer
Universitätsklinik für Innere Medizin
Klinische Abteilung für Gastroenterologie und Hepatologie
Medizinische Universität Graz
Auenbruggerplatz 15
A-8036 Graz
Email: christoph.hoegenauer@medunigraz.at
